Boardroom Alpha
10-K primary document
RCEL · Annual Report (Form 10-K) · Filed February 12, 2026

Avita Medical Inc — 10-K exhibit

rcel-ex10_64.htm
EX-10.64

Exhibit 10.64

AMENDMENT ONE TO EXCLUSIVE DEVELOPMENT AND DISTRIBUTION AGREEMENT

 

This Amendment One (this “Amendment”), amends the Exclusive Development and Distribution Agreement (the “Agreement”), dated July 31, 2024, by and between AVITA Medical Americas, LLC, located at 28159 Avenue Stanford, Suite 220, Valencia, CA 91355 and Collagen Matrix, Inc. dba Regenity Biosciences, located at 115 West Century Road, Suite 380, Paramus, New Jersey 07652 (each individually referred to as a “Party” and collectively as the “Parties”).

 

WHEREAS, the Parties wish to adjust the timing of certain payments under the Agreement; and

 

WHEREAS, The Parties wish to modify aspects of revenue sharing under the Agreement; and

 

WHEREAS, the Parties wish to correct certain scrivener errors regarding the names of a Party.

 

NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

(A)
In Section 2.2(a)(ii) the date “January 4, 2026” is stricken and replaced with “January 4, 2027”.

 

(B)
In Schedule E, the term “60/40” is stricken from the column labeled “[Year #] 3” and replaced with “50/50”.

 

(C)
All references in the Agreement (and any of its attachments, exhibits, or statements of work) to “AVITA Medical, Inc.” are stricken and replaced with “AVITA Medical Americas, LLC”.

This Amendment will become effective as of December 17, 2025 (the "Effective Date"). Except as expressly provided in this Amendment, all of the terms and provisions of the Agreement are and will remain in full force and effect and are hereby ratified and confirmed by the Parties. Without limiting the generality of the foregoing, the amendments contained herein will not be construed as an amendment to or waiver of any other provision of the Agreement or as a waiver of or consent to any further or future action on the part of either Party that would require the waiver or consent of the other Party. On and after the Effective Date, each reference in the Agreement (and any of its attachments, exhibits, or statements of work) to "this Agreement," "the Agreement," "hereunder," "hereof," "herein," or words of like import will mean and be a reference to the Agreement as amended by this Amendment.

 

IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their duly authorized officers below.

 

AVITA Medical Americas, LLC

Collagen Matrix, Inc. dba Regenity Biosciences

By: /s/ Cary Vance\signature

2\

By: /s/ Peggy Hansen\signature1\

Cary G. Vance

Interim Chief Executive Officer

Peggy Hansen

GM CDM / SVP RA/CA/QA

 

 


Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer